MENLO PARK, CA--(Marketwired - Jul 26, 2016) - Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will
report second quarter financial results and provide a corporate update on August 2, 2016. The Company will also host a conference
call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
Conference Call Information
To participate, dial 1-888-771-4371 from the United States or 1-847-585-4405 internationally approximately 10 minutes before
the start of the call. The passcode is 42972085.
A replay will be available through August 16, 2016 at 1-888-843-7419 from the United States and 1-630-652-3042
internationally. The passcode is 42972085.
About Corcept Therapeutics Incorporated
Corcept is a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe
metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol. Korlym® (mifepristone) 300 mg
tablets, a first-generation cortisol modulator, is the company's first FDA-approved medication. The company also has a portfolio
of proprietary compounds that modulate the effects of cortisol but not progesterone. Corcept owns extensive intellectual property
covering the use of cortisol modulators, including mifepristone, in the treatment of a wide variety of serious disorders. It also
holds composition of matter patents covering its selective cortisol modulators.